HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Negotiations

The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble (rerun)

This week, I’m rerunning some popular posts while we prepare for today’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead. Click here to see the original post from January 2026. As I highlighted last week, we are entering the Net Pricing Drug Channel (NPDC) era—a ma

By Drug Channels · Apr 10, 2026 · via Drug Channels
The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble (rerun)

Photo: Pexels

Tags
moneyformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Negotiations
All Negotiations →
PANTHERx CEO: Rare Disease Pharmacy Requires Its Own Model
NegotiationsBriefing
PANTHERx CEO: Rare Disease Pharmacy Requires Its Own Model
Bansi Nagji says rare disease pharmacies must rethink every assumption of traditional specialty models, from s…
Apr 17, 2026
FTC’s Express Scripts Settlement Forces the Era of Net Pricing PBMs
Negotiations
FTC’s Express Scripts Settlement Forces the Era of Net Pricing PBMs
The 2026 FTC settlement compels Express Scripts to base patient costs on net, not list, prices—ending the reba…
Apr 17, 2026
Pharma Hub Transitions: What AssistRx’s 50% Conversion Figure Reveals About an Industry in Flux
Negotiations
Pharma Hub Transitions: What AssistRx’s 50% Conversion Figure Reveals About an Industry in Flux
AssistRx says half of its 2025 patient support programs came via hub transitions, underscoring deep vendor con…
Apr 17, 2026